论文部分内容阅读
目的:探讨单唾液酸四己糖神经节苷脂钠(monosialotetrahexosylganglioside,GM1)联合鼠神经生长因子(nerve growth factor,NGF)在早期治疗Bell面瘫的临床疗效和短期预后。方法 :回顾比较分析2009年1月—2015年9月219例Bell面瘫病例,其中GM1联合NGF组58例,GM1组55例,NGF组51例,未用特殊营养神经药物的基础组55例。所有病例基础治疗相同。通过比较治疗前及治疗后1、2、4周House-Brackmann分级、Sunny Brook综合评分,评价面神经功能的恢复程度。结果:GM1联合NGF组在治疗后2、4周的House-Brackmann分级及Sunny Brook评分均明显优于其他组,差异有统计学意义(P<0.01)。GM1联合NGF组在治疗后4周的痊愈率(91.4%)明显高于GM1组(74.5%)、NGF组(78.4%)及基础组(50.9%),差异有统计学意义(P<0.01)。结论:GM1联合NGF早期治疗Bell面瘫,在面神经功能的早期恢复和改善短期预后方面具有优势。
Objective: To investigate the clinical efficacy and short-term prognosis of early treatment of Bell’s facial palsy with monosialotetrahexosylganglioside (GM1) combined with nerve growth factor (NGF). Methods: A retrospective analysis of 219 cases of Bell facial palsy from January 2009 to September 2015 was performed. Among them, 58 cases were GM1 combined with NGF group, 55 cases were GM1 group, 51 cases were NGF group, and 55 cases were not based on special neurotrophic drugs. All cases of basic treatment the same. The degree of recovery of facial nerve function was evaluated by comparing House-Brackmann grade, Sunny Brook comprehensive score before treatment and 1, 2, 4 weeks after treatment. Results: House-Brackmann grade and Sunny Brook score of GM1 combined with NGF group were significantly better than those of other groups at 2 and 4 weeks after treatment (P <0.01). The recovery rate of GM1 and NGF group at 4 weeks after treatment was significantly higher than that of GM1 group (74.5%), NGF group (78.4%) and basal group (50.9%) (P <0.01) . CONCLUSIONS: Early treatment of Bell facial paralysis by GM1 combined with NGF has advantages in the early recovery of facial nerve function and in the improvement of short-term prognosis.